<div id="readability-page-1"><p>Shares of Arteris, Inc. (NASDAQ:AIP - Get Free Report) were up 7.9% on Thursday after TD Cowen raised their price target on the stock from $22.00 to $40.00. TD Cowen currently has a buy rating on the stock. Arteris traded as high as $37.99 and last traded at $38.3510. Approximately 431,271 shares were traded  during mid-day trading, a decline of 25% from the average daily volume of 575,305 shares. The stock had previously closed at $35.55.</p><ul><li>3 Under-The-Radar Small Caps Making New All-Time Highs</li></ul><p>Several other research analysts also recently commented on the company. Jefferies Financial Group raised their price objective on Arteris from $16.00 to $35.00 and gave the stock a &#34;hold&#34; rating in a research note on Wednesday. Northland Securities  set a $24.00 price objective on Arteris in a research note on Friday, February 13th. Rosenblatt Securities raised their price objective on Arteris from $20.00 to $38.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Arteris in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded Arteris from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and an average target price of $37.75.</p><p><b>Check Out Our Latest Report on AIP</b></p><h2>Insider Transactions at Arteris</h2><ul><li>3 Straightforward ETF Plays to Build AI Exposure Into a Portfolio</li></ul><p>In related news, major shareholder Bayview Legacy, Llc sold 70,000 shares of the firm's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $19.04, for a total value of $1,332,800.00. Following the completion of the sale, the insider directly owned 9,119,071 shares in the company, valued at $173,627,111.84. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO K Charles Janac sold 70,000 shares of the firm's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $19.04, for a total value of $1,332,800.00. Following the completion of the sale, the chief executive officer owned 9,119,071 shares of the company's stock, valued at approximately $173,627,111.84. This represents a 0.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 866,923 shares of company stock worth $18,543,293. 29.10% of the stock is currently owned by company insiders. </p><h2>Arteris News Roundup</h2><p>Here are the key news stories impacting Arteris this week:</p><ul>   <li><span>Positive Sentiment: </span>Arteris delivered a smaller-than-expected Q1 loss of $0.03 per share, beating estimates and improving from a $0.09 loss a year ago, which supports the recent stock strength. <i></i><span>Article Title</span></li>   <li><span>Positive Sentiment: </span>Revenue of $22.94 million topped expectations, reinforcing confidence that demand and execution are improving. <i></i><span>Article Title</span></li>   <li><span>Positive Sentiment: </span>Management raised second-quarter and full-year 2026 revenue guidance, signaling that momentum may continue into the rest of the year. <i></i><span>Article Title</span></li>   <li><span>Positive Sentiment: </span>Rosenblatt Securities sharply raised its price target from $20 to $38 and reiterated a Buy rating, adding to the bullish sentiment around the stock. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>Arteris also released its earnings call transcript and presentation, which may provide more detail on growth drivers and profitability progress. <i></i><span>Article Title</span></li>   <li><span>Neutral Sentiment: </span>The company disclosed a new shareholder-rights risk item, which adds a cautionary note but appears secondary to the strong earnings story. <i></i><span>Article Title</span></li>   <li><span>Negative Sentiment: </span>Insider and major shareholder Bayview Legacy, LLC sold 70,000 shares, a potential overhang even though the sale was modest relative to its remaining stake. <i></i><span>Article Title</span></li> </ul><h2>Institutional Trading of Arteris</h2><ul><li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li></ul><p>A number of institutional investors have recently bought and sold shares of AIP. Roubaix Capital LLC bought a new stake in shares of  Arteris during the 3rd quarter worth approximately $2,361,000.  Granahan Investment Management LLC lifted its stake in shares of  Arteris by 725.7% during the 3rd quarter. Granahan Investment Management LLC now owns 621,625 shares of the company's stock worth $6,278,000 after acquiring an additional 546,341 shares during the last quarter.  Herald Investment Management Ltd lifted its stake in shares of  Arteris by 33.3% during the 3rd quarter. Herald Investment Management Ltd now owns 400,000 shares of the company's stock worth $4,036,000 after acquiring an additional 100,000 shares during the last quarter.  GSA Capital Partners LLP lifted its stake in shares of  Arteris by 59.3% during the 3rd quarter. GSA Capital Partners LLP now owns 132,079 shares of the company's stock worth $1,334,000 after acquiring an additional 49,153 shares during the last quarter.  Finally, Huntleigh Advisors Inc. bought a new stake in shares of  Arteris during the 4th quarter worth approximately $1,832,000. 64.36% of the stock is currently owned by institutional investors. </p><h2>Arteris Trading Up 7.0%</h2><p>The stock has a 50-day simple moving average of $20.74 and a two-hundred day simple moving average of $17.31. The firm has a market capitalization of $1.75 billion, a P/E ratio of -48.22 and a beta of 1.93. </p><p>Arteris (NASDAQ:AIP - Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.05. The firm had revenue of $22.94 million for the quarter, compared to the consensus estimate of $21.03 million.  As a group, research analysts expect that  Arteris, Inc. will post -0.68 EPS for the current year. </p><h2>About Arteris</h2> (Get Free Report)<p>Arteris, Inc is a fabless semiconductor intellectual property (IP) company specializing in on-chip interconnect solutions and system IP for advanced integrated circuits. The company's core products include its FlexNoC network-on-chip (NoC) fabrics, Ncore cache coherent interconnect IP, and CodaCache memory subsystem IP. These technologies enable semiconductor and systems companies to design scalable, energy-efficient chips for applications ranging from automotive and artificial intelligence (AI) to 5G communications and high-performance computing.  </p><p>Founded in 2003 and headquartered in Santa Clara, California, Arteris serves a global customer base across North America, Europe, and Asia.</p><h2>Read More</h2><ul><li>Five stocks we like better than Arteris</li><li>Why Satellogic Could Be One of the Biggest Space Winners of 2026</li><li>Dividend Growth or High Yield: The Income Investor's Bet</li><li>A New Focus for GoPro: Is a Takeover in the Frame?</li><li>Palantir's Critics Are &#34;Right&#34;—But They're Also Still Wrong</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Arteris Right Now?</h2><p>Before you consider Arteris, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arteris wasn't on the list.</p><p>While Arteris currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Shares of Arteris, Inc. (NASDAQ:AIP) rose 7.9% after TD Cowen upgraded its price target from $22 to $40, maintaining a buy rating. The stock traded as high as $37.99, closing at $38.35. Other analysts have also adjusted their price targets, with Jefferies raising it to $35 and Northland Securities setting it at $24. Despite positive earnings and revenue guidance, insider sales raised some caution. The company has a consensus rating of "Hold" with an average target price of $37.75.</p>

Arteris (NASDAQ:AIP) Trading Up 7.9% Following Analyst Upgrade